Full Press Release Details
BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (Nasdaq: QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced that its executive leadership team will participate in the following investor conferences in March:
46th Annual TD Cowen Healthcare ConferenceFormat: Fireside chat and one-on-one meetingsDate: Wednesday, March 4, 2026Time: 11:50 am ETWebcast:Click here
Leerink Global Healthcare Conference 2026Format: Fireside chat and one-on-one meetingsDate: Monday, March 9, 2026Time: 1:00 pm ETWebcast:Click here
Interested parties may access a live and recorded webcast of the fireside chats on theInvestorssection of the company’s website atwww.quanterix.com.
About Quanterix
Quanterix is a global leader in ultra-sensitive biomarker detection, enabling breakthroughs in disease research, diagnostics, and drug development. Its proprietary Simoa® technology delivers industry-leading sensitivity, allowing researchers to detect and quantify biomarkers in blood and other fluids at concentrations far below traditional limits. With approximately 6,000 peer-reviewed publications, Quanterix has been a trusted partner to the scientific community for nearly two decades. In 2025, Quanterix acquired Akoya Biosciences, The Spatial Biology Company®, adding multiplexed tissue imaging with single-cell resolution to its portfolio and 1,396 installed instruments. Together, the combined company offers a uniquely integrated platform that connects biology across blood and tissue—advancing precision medicine from discovery to diagnostics. Learn more atwww.quanterix.com.